Vir Biotechnology stock soars 58%: Is it still a buy?

Vir Biotechnology Inc. shares soared by an impressive 58.17% today, closing at $12.48 after gaining $4.59. The stock skyrocketed on the back of compelling clinical trial data, with VIR-5818 demonstrating a 50% tumor shrinkage rate in HER2-positive patients and a 33% complete response. Meanwhile, VIR-5500 in metastatic castration-resistant prostate cancer achieved a 100% PSA decline, with 58% of patients hitting a PSA50 reduction. These results fueled investor confidence in Vir’s innovative oncology pipeline.

The momentum was further amplified by Vir’s partnership with Sanofi, which validated its T-cell engager technology through promising Phase 1 data in solid tumors. Speculative trading intensified, with pre-market volume surging 61% and the stock holding strong near its volume-weighted average price (VWAP) in after-hours trading. Market buzz on X also highlighted Vir’s competitive edge against rivals like Janux Therapeutics, with analysts speculating that Vir’s results might boost broader interest in T-cell therapies. Liquidity concerns were overshadowed by the stock’s eye-catching price action, with potential targets of $14.50 attracting attention.

Why Jasper Therapeutics stock plunged 60% in one trading session

For investors, today’s explosive move highlights Vir’s growing credibility in the oncology space. The breakthrough data suggests Vir is making significant strides in tackling aggressive cancers, positioning itself as a serious contender among T-cell therapy developers. But while today’s rally underscores strong market enthusiasm, further upside depends on continued success in upcoming trial phases and expanded datasets.

If you’re considering entering the stock, caution is warranted given the volatility. Focus on the upcoming trial updates for VIR-5818 and VIR-5500, which will likely shape the narrative around Vir’s long-term potential. For those already invested, today’s performance signals renewed optimism but also the need to monitor technical levels and liquidity for a clearer path forward.

Disclaimer: The content of this article is for informational purposes only and should not be construed as investment advice. We do not endorse any specific investment strategies or make recommendations regarding the purchase or sale of any securities.

Featured image credit: Sangharsh Lohakare/Unsplash